Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy
Elisabetta Signoriello(ATS Sardegna (Italy)), Alessio Signori(University of Genoa), Girolama Alessandra Marfia(Erasmus University Rotterdam), Damiano Baroncini, Arianna Sartori(Azienda Sanitaria Universitaria Integrata di Trieste), Erica Curti(University of Parma), Jessica Frau(University of Cagliari), Simone Cepparulo(University of Campania "Luigi Vanvitelli"), Francesco Saccà(Federico II University Hospital), Doriana Landi(Amsterdam UMC Location Vrije Universiteit Amsterdam), Roberta Lanzillo(University of Naples Federico II), Antonio Carotenuto, Simona Bonavita, Maria Pia Sormani(University of Genoa), Giacomo Lus(University of Campania "Luigi Vanvitelli"), Viviana Nociti(Agostino Gemelli University Polyclinic), Francesca Caleri(Krankenhaus Meran), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), Giorgia Teresa Maniscalco(Ospedale Antonio Cardarelli), Carolina Gabri Nicoletti(University of Rome Tor Vergata)
Cited by 19
Related Papers
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706
Multiple sclerosis progression: time for a new mechanism-driven framework
|The Lancet Neurology|2022|624
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
|The Lancet|2002|552
MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process
|Nature Reviews Neurology|2015|423